Lack of Association Between Duration of Untreated Illness and Severity of Cognitive and Structural Brain Deficits at the First Episode of Schizophrenia
Publication: American Journal of Psychiatry
Abstract
OBJECTIVE: The purpose of the study was to determine whether the duration of illness before antipsychotic drug treatment for schizophrenia was associated with the severity of cognitive deficits and volumetric brain structure anomalies observed in some patients with a first episode of schizophrenia. METHOD: Duration of psychotic symptoms and of other symptoms marking a behavioral change was estimated from structured interviews with 50 patients who had a first episode of schizophrenia and their family members. Interviews were conducted within a month of the patients’ hospitalization. Duration of untreated psychotic symptoms and of behavioral change was correlated with neuropsychological summary scores from a comprehensive cognitive battery and with measurements of lateral ventricular, temporal lobe, and cerebral hemispheric volumes. RESULTS: No significant correlations were observed between measures of untreated illness and the severity of either cognitive or structural brain deficits at baseline. CONCLUSIONS: The duration of untreated symptoms of schizophrenia, for which an association with an uncontrolled toxic brain process has been proposed, is unlikely to explain why first-episode patients with schizophrenia have widespread deficits in cognitive functioning and have detectable ventricular enlargement and some loss of cortical mass.
Kraepelin described dementia praecox as a variable but progressively dementing disorder with brain pathology (1, 2). Severely disturbed patients with a chronic deteriorating course of schizophrenia have been observed less frequently in recent years (3, 4), perhaps because neuroleptic treatment, now started early in the course of illness, may not only suppress psychotic symptoms but also influence the course of illness. Some researchers believe that medication may do far more than previously thought by preventing an active toxic brain process to continue (reviewed in Wyatt [5, 6]). In 1986, Crow and colleagues (7) published results from a randomized controlled trial of a standard neuroleptic for maintenance treatment after a first hospitalization for schizophrenia. Unexpectedly, the most important determinant of relapse was duration of untreated psychosis before the start of neuroleptic medication. Wyatt and colleagues, in reviews of the first neuroleptic treatment trials (5, 6, 8, 9), concluded that early treatment does alter the course of illness. They noted significantly better outcomes in studies of first-episode patients, compared with outcomes reported in studies of neuroleptic trials with patients who had a chronic illness. Other studies have found that longer duration of untreated psychosis is related to longer time to remission, a lesser degree of remission (10), poorer social and work functioning before the first admission, a more insidious onset of psychosis, and more negative symptoms at first clinical presentation (11, 12). McGlashan (13) has asserted that an extensive duration of untreated psychosis is a major public health problem.
Brain structural abnormalities are detectable in patients with schizophrenia at the time of the first hospitalization. These abnormalities include ventricular enlargement, loss of cerebral asymmetries, and regional cortical and nonlocalized reductions in gray matter volume (14–23). Neuropsychological deficits, which could provide a window into underlying brain pathology, similarly are known to be present by the time of the first episode. In particular, deficits in language, memory, executive function, and overall intelligence measures have been noted (24–29). Although cognitive processing has not been shown to deteriorate after the first hospitalization (26, 30, 31), some studies have provided evidence that brain structural changes may be progressive after illness onset in some patients (reviewed in reference 32). In fact, early pneumoencephalographic studies revealed ventricular enlargement over time in patients with poor prognosis (33–35). As early as 1983, Woods and Wolf (36) proposed that ventricular enlargement in schizophrenia as seen on computerized tomography scans was progressive. Unfortunately, these studies were ignored because schizophrenia was generally viewed as a neurodevelopmental disorder (37) and little thought was given to the idea that the disorder could have both developmental and progressive components (38, 39). Earlier findings that poor premorbid adjustment was associated with ventricular enlargement were interpreted to imply the existence of a subgroup of patients with an early developmental defect, rather than to suggest the possibility of an underlying progressive brain pathology that was responsible for the poor premorbid signs (40, 41).
The study reported here tested the hypothesis that symptoms of schizophrenia before a first hospitalization, perhaps reflecting an active brain disturbance toxic to neuronal growth and repair, would result in cognitive and structural brain defects. Thus, increasing duration of untreated illness would be correlated with increasing deficits in cognitive performance and brain structural deviance at the time of first hospitalization. Since our previous studies (42) and those of other investigators (reviewed in reference 32) have shown progressing ventricular enlargement and hemispheric and temporal lobe volume reductions in subjects with first-episode schizophrenia, we chose these three variables as indicators of brain structural change and correlated their values at the first hospitalization with duration of untreated illness. Similarly, we correlated duration of untreated illness with patients’ scores on a battery of neuropsychological tests that has been used previously to show generalized cognitive deficits at the time of a first episode (24).
Method
Fifty patients with a first episode of schizophrenia who were consecutively admitted for hospitalization in Suffolk County, N.Y., participated in a longitudinal follow-up study that included an annual battery of clinical and neuropsychological evaluations and magnetic resonance imaging (MRI) scans. Structured psychiatric interviews with the Schedule for Affective Disorders and Schizophrenia—Lifetime Version (SADS-L) (43) were conducted by trained research staff. DSM-III-R diagnoses were made by a research psychiatrist after review of the SADS-L results, medical records, and structured interviews with family members about the patient’s symptoms. The diagnoses were confirmed by a second diagnostician. When there was a disagreement, a third diagnostician was consulted, and a consensus diagnosis was made. Diagnosticians were blind to the MRI results and neuropsychological test data. Of the 50 patients, 32 were diagnosed with schizophreniform disorder, six with subchronic schizophrenia, four with chronic schizophrenia, seven with schizoaffective disorder, and one with psychosis not otherwise specified. Written informed consent was obtained from all subjects for all evaluations by using separate consent forms that had been previously approved by the State University of New York at Stony Brook. Additional details about the subjects are provided elsewhere (24, 30, 42, 44).
Thirty-two men and 18 women with a mean age of 27.4 years (SD=7) participated in the study. MRI scan measurements previously obtained from 20 healthy comparison subjects (12 men and eight women, mean age=26.5 years, SD=5) (38) were used for calculating Z scores, as described below.
For each patient in the study, initiation of treatment occurred on admission to the hospital. Two estimates of duration of untreated illness were derived from information on the patient’s psychosocial and developmental history that was obtained in structured interviews with the patient and the closest available family member. The first estimate was the duration of untreated psychosis, assessed as the duration (in months) of delusions, hallucinations, or formal thought disorder before treatment. The second estimate was the duration (in years) of behavioral change, assessed as the duration of any significant changes in school or work performance, social relationships, or personal habits.
Estimates of the duration of untreated psychosis and of behavioral change were reached by consensus of a research psychiatrist and trained research assistant after they independently reviewed all records. The mean duration of untreated psychosis was 11.4 months (SD=16.2, range=<1–72), and the mean duration of behavioral change was 3.4 years (SD=6.1, range=<1–41).
All subjects were assessed within a month of hospitalization and after stabilization with a conventional neuroleptic medication. However, eight subjects did not complete the full neuropsychological battery at that time, and 10 patients had incomplete MRI scans (missing measurements of the frontal and occipital poles of the cerebral hemispheres and of a portion of the cerebellum for seven patients, and missing temporal lobe measurements for three patients). Therefore, these subjects were eliminated from analyses that included those variables.
Before performing correlational analyses, the raw MRI volumes were converted to Z scores on the basis of the mean and standard deviation from the group of 20 comparison subjects measured at the same time by the same investigator (42). Multiple regression analysis was used to regress the Z scores on subjects’ height to account for variance in body size that would contribute to differences in size of brain structures. The residuals were then correlated with the duration of untreated psychosis and the duration of behavioral change by using Spearman rank-order correlations. The MRI variables were left and right hemispheric volumes, left and right temporal lobe volumes, and left and right lateral ventricular volumes. Additional details about the methods used to produce the MRI measurements are provided by DeLisi and colleagues (44, 45).
In addition, Spearman rank-order correlations were computed by using the baseline scores on the neuropsychological summary scales measuring deficits in language, executive, verbal memory, spatial memory, concentration/speed, and sensory/perceptual abilities. Scores on the neuropsychological summary scales were normalized by calculating Z scores on the basis of scores from a battery of standardized tests for each category (24, 30, 44). Spearman rank-order correlation was chosen for the analyses because preliminary univariate analyses showed that many of the variables were not normally distributed.
The duration of untreated psychosis was also treated as a dichotomous variable, with 1 year as the cutoff point. Patients were divided into two groups: those with <1 year of untreated psychosis (N=15) and those with >1 year of untreated psychosis (N=35). For the brain structure variables, analyses of covariance with height as covariate were performed to test for differences between the two groups. For the neuropsychological summary measures, independent t tests were used to test for differences.
Results
No statistically significant correlations were found between either measure of duration of untreated illness and baseline brain structure volumetric measurements. There were also no significant relationships between the measures of duration of untreated illness and the neuropsychological summary scores (Table 1).
In addition, separate analyses by sex did not reveal any significant relationships, although the female subjects had a significantly longer mean duration of untreated psychosis than the male subjects (mean=18.7 months, SD=22.1, compared with mean=7.3 months, SD=9.9) (t=2.5, df=48, p<0.01).
No statistically significant differences were found between patients with <1 year and >1 year of untreated psychosis on either the brain structure variables or the neuropsychological test variables.
Discussion
The analysis failed to provide evidence for a relationship between duration of untreated illness and the severity of cognitive deficits or structural brain anomalies in subjects with schizophrenia during their first episode of illness. Although some researchers have implied that delayed treatment in a potential first episode of schizophrenia allows brain damage to accumulate (5, 6), no study has yet yielded direct evidence that this has occurred. Most reports have shown a significant correlation of duration of untreated illness and outcome, such that the longer the untreated illness, the poorer the outcome (7, 8, 10–12, 46). Waddington and colleagues (47) found that the severity of negative symptoms, perhaps reflective of an underlying neurodegenerative process, was correlated with duration of untreated illness. Another study provided evidence for an association between the level of general cognitive impairment, although not of executive dyscontrol, and duration of untreated psychosis (48). However, in these two reports, the subjects had been ill for many years and had been treated for their illness by the time of assessment; thus the observed correlations could be influenced by events that occurred after the initiation of treatment. In the study reported here, all patients were examined at the time of their first psychotic episode. Thus, indicators of cognitive or neurobiological deficit could not be the result of any process occurring as a result of treatment and chronicity in general.
Our results were similar to those of Loebel et al. (10), who found that the average duration of untreated psychosis was approximately 1 year and the average time between onset of behavioral change (prodromal symptoms) and treatment was approximately 3 years. Our corresponding averages were 11.4 months (SD=16.2) for duration of untreated psychosis and 3.4 years (SD=6.1) for duration of behavioral changes. However, unlike Loebel et al. (10) and Larsen et al. (11), we did not find that duration of untreated illness was substantially longer for male patients than for female patients. It is unclear what might account for the longer period of untreated psychosis for the female patients in our study. However, several other studies have not found a longer period of untreated illness in male patients than in female patients (49–51).
A recent epidemiological survey conducted in the same geographical region as our study failed to find an association between duration of untreated illness and 24-month illness outcome (52). Another independent study of neuroleptic-naive patients with DSM-IV schizophrenia showed no relationship between untreated illness duration and quality of life, symptom severity, or remission 6 months after the patients’ initial hospitalization (51). Nevertheless, much of the literature does support the idea that untreated psychosis may be associated with worse clinical outcomes. Since we do not report data on clinical outcome, we cannot comment on these findings. It may be that brain structural pathology and cognitive deficits at the first episode are predictive of outcome. However, our data suggest that poorer clinical outcomes cannot be attributed to the effects of duration of untreated psychosis on cognition functioning or on brain structural variables.
One possible explanation for our negative results is that the small size of the study group did not afford sufficient power to detect statistically significant correlations. As Table 1 shows, most correlations were close to 0 and all 95% confidence intervals included estimates of 0. Our study group did provide 80% power to detect a correlation of 0.40 or higher. Nonetheless, it is possible that a larger study group size with greater power could detect statistically significant correlations.
The present study thus provides no support for the hypothesis that a period of untreated illness is toxic to brain structure or function. However, this retrospective analysis will need support from longitudinal prospective studies of high-risk individuals. In addition, studies that involve larger numbers of patients, which would permit the analysis of data on subgroups of subjects with particular clinical presentations, and studies that use more detailed methods for brain structure analysis could yield results to support this hypothesis.
Footnote
Received Feb. 15, 2000; revision received June 29, 2000; accepted July 5, 2000. From the Department of Psychiatry and Behavioral Sciences, State University of New York at Stony Brook; the University of California, Davis–Napa Psychiatric Research Center, Napa, CA; and the Department of Psychiatry, Washington University School of Medicine, St. Louis. Address reprint requests to Dr. DeLisi, Department of Psychiatry, HSC, T-10, State University of New York at Stony Brook, Stony Brook, NY 11794; [email protected] (e-mail). Supported by NIMH grant MH-44233. The authors thank Sue Thiemann for statistical consultation.
References
1.
Kraepelin E: Psychiatrie: Ein Lehrbuch fur Studirende und Aerzte, vol II. Leipzig, Germany, Verlagvon Barth, 1889
2.
Kraepelin E: Dementia Praecox and Paraphrenia (1919). Translated by Barclay RM; edited by Robertson GM. New York, Robert E Krieger, 1971
3.
Hegarty JD, Baldessarini RJ, Tohen M, Waternaux C, Oepen G: One hundred years of schizophrenia: a meta-analysis of the outcome literature. Am J Psychiatry 1994; 151:1409–1416
4.
Wing JK: Has the outcome of schizophrenia changed? Br Med Bull 1987; 43:741–753
5.
Wyatt RJ: Neuroleptics and the natural course of schizophrenia. Schizophr Bull 1991; 17:325–351
6.
Wyatt RJ: Early intervention with neuroleptics may decrease the long-term morbidity of schizophrenia. Schizophr Res 1991; 5:201–202
7.
Crow TJ, MacMillan JF, Johnson AL, Johnstone EC: A randomised controlled trial of prophylactic neuroleptic treatment. Br J Psychiatry 1986; 148:120–127
8.
Wyatt RJ, Damiani LM, Henter ID: First-episode schizophrenia: early intervention and medication discontinuation in the context of course of treatment. Br J Psychiatry Suppl 1998; 172:77–83
9.
Wyatt RJ, Henter ID: The effects of early and sustained intervention on the long-term morbidity of schizophrenia. J Psychiatr Res 1998; 32:169–177
10.
Loebel AD, Lieberman JA, Alvir JMJ, Mayerhoff DI, Geisler SH, Szymanski SR: Duration of psychosis and outcome in first-episode schizophrenia. Am J Psychiatry 1992; 149:1183–1188
11.
Larsen TK, McGlashan TH, Moe LC: First-episode schizophrenia, I: early course parameters. Schizophr Bull 1996; 22:241–256
12.
Haas GL, Garratt LS, Sweeney JA: Delay to first antipsychotic medication in schizophrenia: impact on symptomatology and clinical course of illness. J Psychiatr Res 32; 1998:3–4
13.
McGlashan TH: Duration of untreated psychosis in first-episode schizophrenia: marker or determinant of course? Biol Psychiatry 1999; 46:899–907
14.
Weinberger DR, DeLisi LE, Perman GP, Targum S, Wyatt RJ: Computed tomography in schizophreniform disorder and other acute psychiatric disorders. Arch Gen Psychiatry 1982; 39:778–783
15.
DeLisi LE, Hoff AL, Schwartz JE, Shields GW, Halthore SN, Gupta SM, Henn FA, Anand AK: Brain morphology in first-episode schizophrenic-like psychotic patients: a quantitative magnetic resonance imaging study. Biol Psychiatry 1991; 29:159–175
16.
Degreef G, Ashtari M, Bogerts B, Bilder RM, Jody DN, Alvir JM, Lieberman JA: Volumes of ventricular system subdivisions measured from magnetic resonance images in first-episode schizophrenic patients. Arch Gen Psychiatry 1992; 49:531–537
17.
Bilder RM, Wu H, Bogerts B, Degreef G, Ashtari M, Alvir JMJ, Snyder PJ, Lieberman JA: Absence of regional hemispheric volume asymmetries in first-episode schizophrenia. Am J Psychiatry 1994; 151:1437–1447
18.
DeLisi LE, Sakuma M, Kushner M, Finer DL, Hoff AL, Crow TJ: Anomalous cerebral asymmetry and language processing in schizophrenia. Schizophr Bull 1997; 23:255–271
19.
Bogerts B, Ashtari M, Degreef G, Alvir JM, Bilder RM, Lieberman JA: Reduced temporal limbic structure volumes on magnetic resonance images in first episode schizophrenia. Psychiatry Res 1990; 35:1–13
20.
Hirayasu Y, Shenton ME, Salisbury DF, Dickey CC, Fischer IA, Mazzoni P, Kisler T, Arakaki H, Kwon JS, Anderson JE, Yurgelun-Todd D, Tohen M, McCarley RW: Lower left temporal lobe MRI volumes in patients with first-episode schizophrenia compared with psychotic patients with first-episode affective disorder and normal subjects. Am J Psychiatry 1998; 155:1384–1391
21.
Gur RE, Cowell P, Turetsky BI, Gallagher F, Cannon T, Bilker W, Gur RC: A follow-up magnetic resonance imaging study of schizophrenia: relationship of neuroanatomical changes to clinical and neurobehavioral measures. Arch Gen Psychiatry 1998; 55:145–152
22.
Lim KO, Tew W, Kushner M, Chow K, Matsumoto B, DeLisi LE: Cortical gray matter volume deficit in patients with first-episode schizophrenia. Am J Psychiatry 1996; 153:1548–1553
23.
Zipursky RB, Lambe EK, Kapur S, Mikulis DJ: Cerebral gray matter volume deficits in first episode psychosis. Arch Gen Psychiatry 1998; 55:540–546
24.
Hoff AL, Riordan H, O’Donnell DW, Morris L, DeLisi LE: Neuropsychological functioning of first-episode schizophreniform patients. Am J Psychiatry 1992; 149:898–903
25.
Albus M, Hubmann W, Ehrenberg C, Forcht U, Mohr F, Sobizack N, Wahlheim C, Hecht S: Neuropsychological impairment in first-episode and chronic schizophrenic patients. Eur Arch Psychiatry Clin Neurosci 1996; 246:249–255
26.
Censits DM, Ragland JD, Gur RC, Gur RE: Neuropsychological evidence supporting a neurodevelopmental model of schizophrenia: a longitudinal study. Schizophr Res 1997; 24:289–298
27.
Hutton SB, Puri BK, Duncan LJ, Robbins TW, Barnes TR, Joyce EM: Executive function in first-episode schizophrenia. Psychol Med 1998; 28:463–473
28.
Bilder RM, Lipschutz-Broch L, Reiter G, Geisler S, Mayerhoff D, Lieberman JA: Neuropsychological deficits in the early course of first-episode schizophrenia. Schizophr Res 1991; 5:198–199
29.
Saykin AJ, Shtasel DL, Gur RE, Kester DB, Mozley LH, Stafiniak P, Gur RC: Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia. Arch Gen Psychiatry 1994; 51:124–131
30.
Hoff AL, Sakuma M, Wieneke M, Horon R, Kushner M, DeLisi LE: Longitudinal neuropsychological follow-up study of patients with first-episode schizophrenia. Am J Psychiatry 1999; 156:1336–1341
31.
Gold S, Arndt S, Nopolous P, O’Leary DS, Andreasen NC: Longitudinal study of cognitive function in first-episode and recent-onset schizophrenia. Am J Psychiatry 1999; 156:1342–1348
32.
DeLisi LE: Defining the course of brain structural change and plasticity in schizophrenia. Psychiatry Res Neuroimaging 1999; 92:1–9
33.
Huber G: Pneumoencephalographische und Psychopathologische Bilder bei Endogen Psychosen. Berlin, Springer, 1957
34.
Haug JO: Pneumoencephalographic studies in mental disease. Acta Psychiatr Neurol Scand Suppl 1963; 38:11–104
35.
Moore MT, Nathan D, Elliott AR, Laubach C: Encephalographic studies in mental disease: an analysis of 152 cases. Am J Psychiatry 1935; 92:43–67
36.
Woods BT, Wolf J: A reconsideration of the relation of ventricular enlargement to duration of illness in schizophrenia. Am J Psychiatry 1983; 140:1564–1570
37.
Weinberger DR: Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 1987; 44:660–669
38.
DeLisi LE, Lieberman J: American College of Neuropsychopharmacology satellite meeting: longitudinal perspectives on the pathophysiology of schizophrenia: examining the neurodevelopmental versus neurodegenerative hypotheses. Schizophr Res 1991; 5:183–210
39.
DeLisi LE: Is schizophrenia a lifetime disorder of brain plasticity, growth and aging? Schizophr Res 1997; 23:119–129
40.
DeLisi LE, Schwartz CC, Targum SD, Byrnes SM, Cannon-Spoor E, Weinberger DR, Wyatt RJ: Prediction of outcome in acute schizophreniform disorder. Psychiatry Res 1983; 9:169–171
41.
Weinberger DR, Cannon-Spoor E, Potkin SG, Wyatt RJ: Poor premorbid adjustment and CT scan abnormalities in chronic schizophrenia. Am J Psychiatry 1980; 137:1410–1413
42.
DeLisi LE, Sakuma M, Tew W, Kushner M, Hoff AL, Grimson R: Schizophrenia as a chronic active brain process: a study of progressive brain structural change subsequent to the onset of schizophrenia. Psychiatry Res Neuroimaging 1997; 74:129–140
43.
Spitzer RL, Endicott J: Schedule for Affective Disorders and Schizophrenia—Lifetime Version. New York, New York State Psychiatric Institute, Biometrics Research, 1978
44.
Hoff AL, Riordan H, O’Donnell D, Neale C, Kushner M, DeLisi LE: Anomalous lateral sulcus asymmetry and cognitive function in first-episode schizophrenia. Schizophr Bull 1992; 18:257–272
45.
DeLisi LE, Tew W, Xie S-H, Hoff AL, Sakuma M, Kushner M, Lee G, Shedlack K, Smith AM, Grimson R: A prospective follow-up study of brain morphology and cognition in first episode schizophrenic patients. Biol Psychiatry 1995; 38:349–360
46.
Wyatt RJ, Green MF, Tuma AH: Long-term morbidity associated with delayed treatment of first episode schizophrenic patients: a reanalysis of the Camarillo State Hospital data. Psychol Med 1997; 27:261–268
47.
Waddington JL, Youssef HA, Kinsella A: Sequential cross-sectional and 10-year prospective study of severe negative symptoms in relation to duration of initially untreated psychosis in chronic schizophrenia. Psychol Med 1995; 25:849–857
48.
Scully PJ, Coakley G, Kinsella A, Waddington JL: Psychopathology, executive (frontal) and general cognitive impairment in relation to duration of initially untreated versus subsequently treated psychosis in chronic schizophrenia. Psychol Med 1997; 27:1303–1310
49.
Beiser M, Erickson D, Fleming JAE, Iacono WG: Establishing the onset of psychotic illness. Am J Psychiatry 1993; 150:1349–1354
50.
Hafner H, Maurer K, Loffler W, Riecher-Rossler A: The influence of age and sex on the early onset of early course of schizophrenia. Br J Psychiatry 1993; 162:80–86
51.
Ho B-C, Andreasen NC, Flaum M, Nopoulos P, Miller D: Untreated initial psychosis: its relation to quality of life and symptom remission in first-episode schizophrenia. Am J Psychiatry 2000; 157:808–815
52.
Craig TJ, Bromet EJ, Fennig S, Tanenberg-Karant M, Lavelle J, Galambos N: Is there an association between duration of untreated psychosis and 24-month clinical outcome in a first-admission series? Am J Psychiatry 2000; 157:60–66
Information & Authors
Information
Published In
History
Published online: 1 November 2000
Published in print: November 2000
Authors
Metrics & Citations
Metrics
Citations
Export Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.
For more information or tips please see 'Downloading to a citation manager' in the Help menu.
View Options
View options
PDF/EPUB
View PDF/EPUBGet Access
Login options
Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.
Personal login Institutional Login Open Athens loginNot a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).